Integra Lifesciences Holdings (IART) Operating Leases (2019 - 2026)

Integra Lifesciences Holdings (IART) has 8 years of Operating Leases data on file, last reported at $160.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 8.84% year-over-year to $160.1 million; the trailing twelve-month figure through Mar 2026 stood at $160.1 million (down 8.84% YoY), and the FY2025 full-year result was $177.1 million, up 6.08% from the prior year.
• Operating Leases slipped to $160.1 million in Q1 2026, from $177.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $177.1 million in Q4 2025 to a low of $87.8 million in Q1 2022.
• A 5-year average of $163.0 million and a median of $167.8 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases soared 78.7% in 2023 and declined 8.84% in 2026, its largest moves.
• Tracing IART's Operating Leases over 5 years: stood at $172.0 million in 2022, then fell by 3.02% to $166.8 million in 2023, then rose by 0.05% to $166.9 million in 2024, then climbed by 6.08% to $177.1 million in 2025, then slipped by 9.58% to $160.1 million in 2026.
• Business Quant data shows IART's Operating Leases at $160.1 million in Q1 2026, $177.1 million in Q4 2025, and $174.8 million in Q3 2025.